Product Code: SR112023A4417
Abstract
The global carrier screening market size reached US$ 1.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.1 Billion by 2028, exhibiting a growth rate (CAGR) of 10.53% during 2022-2028.
Carrier screening is a genetic testing technique used for the identification abnormal genes in fetuses that can cause autosomal recessive diseases. It is a predictive and pre-symptomatic testing solution used by pregnant individuals and couples to analyze the risks of their child inheriting genetic disorders from the parents. It involves testing a sample of saliva, blood or cheek tissue to detect the presence of an abnormal gene for disorders, such as cystic fibrosis, sickle cell anemia and Tay-Sachs disease. These samples are screened through molecular and biochemical processes based on deoxyribonucleic acid (DNA) sequencing, polymerase chain reaction (PCR) and microarray technologies. They are used for expanded, customized panel, predesigned panel and targeted disease carrier screening for various pulmonary, hematological and neurological disorders.
Carrier Screening Market Trends:
The increasing prevalence of fetal chromosomal abnormalities and genetic disorders across the globe is one of the key factors driving the growth of the market. Moreover, the rising consciousness among the masses regarding the benefits of early detection and diagnosis of diseases is providing a thrust to the market growth. In line with this, molecular screening tests are widely conducted to identify DNA mutations in the genetic codes and detect the mutations that can cause heart defects, pre-leukemia, hearing defects and down syndrome. Carrier screening also aids in providing adequate prenatal and reproductive care, which facilitates the proper management of heritable diseases. Additionally, various technological advancements, such as the development of next-generation sequencing (NGS) techniques for genetic disease screening, are also favoring the market growth. Other factors, including extensive research and development (R&D) activities in the field of biotechnology and bioinformatics, along with significant growth in the medical infrastructure, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global carrier screening market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, medical condition, technology and end user.
Breakup by Type:
Expanded Carrier Screening
Customized Panel Testing
Predesigned Panel Testing
Targeted Disease Carrier Screening
Breakup by Medical Condition:
Pulmonary Conditions
Hematological Conditions
Neurological Conditions
Others
Breakup by Technology:
DNA Sequencing
Polymerase Chain Reaction
Microarrays
Others
Breakup by End User:
Hospitals and Clinics
Reference Laboratories
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Fulgent Genetics, Gene By Gene Ltd. (MyDNA), Illumina Inc., Invitae Corporation, MedGenome Labs Ltd., Myriad Genetics Inc., Natera Inc., OPKO Health Inc., Quest Diagnostics, Sema4 and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
- How has the global carrier screening market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global carrier screening market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the medical condition?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global carrier screening market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Carrier Screening Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Expanded Carrier Screening
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Customized Panel Testing
- 6.1.2.2 Predesigned Panel Testing
- 6.1.3 Market Forecast
- 6.2 Targeted Disease Carrier Screening
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Medical Condition
- 7.1 Pulmonary Conditions
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Hematological Conditions
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Neurological Conditions
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Technology
- 8.1 DNA Sequencing
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Polymerase Chain Reaction
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Microarrays
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals and Clinics
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Reference Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Fulgent Genetics
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.2 Gene By Gene Ltd. (MyDNA)
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 Illumina Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Invitae Corporation
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.5 MedGenome Labs Ltd.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Myriad Genetics Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Natera Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.8 OPKO Health Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Quest Diagnostics
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sema4
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.11 Thermo Fisher Scientific Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis